Rifaximin

SKU: orb1309584

Description

Rifaximin

Research Area

Cell Biology, Infectious Disease & Virology, Molecular Biology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 80621-81-4
• MW: 785.88
• Purity: 99.56% (May vary between batches)
• Formula: C₄₃H₅₁N₃O₁₁
• SMILES: COC1\C=C/OC2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C)C1=C2N=C2C=C(C)C=CN12
• Target: DNA/RNA Synthesis,Antibacterial,Antibiotic
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2.5 mg/mL (3.18 mM);Ethanol:3 mg/mL (3.82 mM);DMSO:50 mg/mL (63.62 mM)

Bioactivity

• In Vivo:
  Rifaximin exhibits broad-spectrum activity against aerobic and anaerobic Gram-positive and Gram-negative microorganisms.Rifaximin exhibits a low MIC against Gram-positive bacteria, with a dose range of 0.01 μg/mL to 0.5 μg/mL for MIC 90.Rifaximin binds to the β-subunit of the bacterial DNA-dependent RNA polymerase and inhibits the start of the chain of RNA synthesis. Rifaximin inhibits LPS-induced cytokine and chemokine expression by inhibiting NF-κB DNA binding activity.50 μM Rifaximin reduces changes in pro-inflammatory factor production induced by LPS stimulation in the IEC, such as TNF-α, IL-8, Rantes, and PGE2 in normal intestinal epithelial cells.100 μM Rifaximin is also shown to inhibit LPS-induced cytokine expression by inhibiting NF-κB DNA binding activity. μM Rifaximin effectively reduced the expression of TNFα, IL-8, MIP-3α and RANTES by lipopolysaccharide-induced stimulation.
  Read more...
• In Vitro:
  Rifaximin exhibits broad-spectrum activity against aerobic and anaerobic Gram-positive and Gram-negative microorganisms.Rifaximin exhibits a low MIC against Gram-positive bacteria, with a dose range of 0.01 μg/mL to 0.5 μg/mL for MIC 90.Rifaximin binds to the β-subunit of the bacterial DNA-dependent RNA polymerase and inhibits the start of the chain of RNA synthesis. Rifaximin inhibits LPS-induced cytokine and chemokine expression by inhibiting NF-κB DNA binding activity.50 μM Rifaximin reduces changes in pro-inflammatory factor production induced by LPS stimulation in the IEC, such as TNF-α, IL-8, Rantes, and PGE2 in normal intestinal epithelial cells.100 μM Rifaximin is also shown to inhibit LPS-induced cytokine expression by inhibiting NF-κB DNA binding activity. μM Rifaximin effectively reduced the expression of TNFα, IL-8, MIP-3α and RANTES by lipopolysaccharide-induced stimulation.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Antibiotic, Bacterial, DNASynthesis, DNA/RNA Synthesis, DNA Synthesis, diarrhea, inhibit, infection, gastrointestinal, Inhibitor, RNASynthesis, RNA Synthesis, Rifaximin

Compound Identifiers

PubChem CID

42608884